Molecular imaging in cancer

Science

Volumn 312, Issue 5777, 2006, Pages 1168-1171

  Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMAGE PROCESSING; IMAGING TECHNIQUES; INFORMATION DISSEMINATION; MEDICAL APPLICATIONS; ONCOLOGY; PATIENT TREATMENT; PHARMACODYNAMICS;

ANATOMICAL IMAGING METHODS; CLINICAL MANAGEMENT; IMAGING AGENTS; MOLECULAR IMAGING;

TUMORS;

EPOTHILONE DERIVATIVE; PROTEIN KINASE; PROTEINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CANCER; DISEASE TREATMENT; DRUG DEVELOPMENT; IMAGING METHOD; TUMOR;

ANGIOGENESIS; APOPTOSIS; CANCER; CANCER DIAGNOSIS; CARCINOGENESIS; DIAGNOSTIC IMAGING; HUMAN; METASTASIS; MOLECULAR IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR LOCALIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DRUG EVALUATION, PRECLINICAL; HUMANS; INDICATORS AND REAGENTS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TUMOR MARKERS, BIOLOGICAL;

EID: 33744487875     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1125949     Document Type: Review

References (43)

1. M. E. Juweid, B. D. Cheson, N. Engl. J. Med. 354, 496 (2006).
2. R. Weissleder, Nat. Rev. Cancer 2, 11 (2002).
3. F. A. Jaffer, R. Weissleder, JAMA 293, 855 (2005).
4. R. Etzioni et al., Nat. Rev. Cancer 3, 243 (2003).
5. A. Sweet-Cordero et al., Nat. Genet. 37, 48 (2005).
6. J. Grimm et al., Proc. Natl. Acad. Sci. U.S.A. 102, 14404 (2005).
7. K. Marten et al., Gastroenterology 122, 406 (2002).
8. H. Alencar, U. Mahmood, Y. Kawano, T. Hirata, R. Weissleder, Neoplasia 7, 977 (2005).
9. J. A. Evans, N. S. Nishioka, Curr. Opin. Gastroenterol. 21, 578 (2005).
10. M. G. Harisinghani et al., N. Engl. J. Med. 348, 2491 (2003).
11. A. Quon, S. S. Gambhir, J. Clin. Oncol. 23, 1664 (2005).
12. U. Guller et al., Breast Cancer Res. Treat. 71, 171 (2002).
13. H. A. Wieder et al., J. Clin. Oncol. 22, 900 (2004).
14. N. Avril et al., J. Clin. Oncol. 23, 7445 (2005).
15. G. J. Kelloff, C. C. Sigman, Eur. J. Cancer 41, 491 (2005).
16. The Biomedical Research and Development Guide is available at (www.biag.org/BIAG/rd.htm).
17. T. J. Lynch et al., J. Med. 350, 2129 (2004).
18. J. W. Park et al., Clin. Cancer Res. 10, 3885 (2004).
19. M. Rudin, R. Weissleder, Nat. Rev. Drug Discov. 2, 123 (2003).
20. T. F. Massoud, S. S. Gambhir, Genes Dev. 17, 545 (2003).
21. R. Weissleder, V. Ntziachristos, Nat. Med. 9, 123 (2003).
22. S. Gross, D. Piwnica-Worms, Cancer Cell 7, 5 (2005).
23. H. R. Herschman, Science 302, 605 (2003).
24. P. R. Contag, Drug Discov. Today 7, 555 (2002).
25. K. D. Wu et al., Proc. Natl. Acad. Sci. U.S.A. 102, 10640 (2005).
26. K. Shah, C. H. Tung, X. O. Breakefield, R. Weissleder, Mol. Ther. 11, 926 (2005).
27. G. Lappin, R. C. Garner, Nat. Rev. Drug Discov. 2, 233 (2003).
28. A. Saleem et al., J. Clin. Oncol. 19, 1421 (2001).
29. D. J. Propper et al., J. Clin. Oncol. 21, 203 (2003).
30. Information on IND studies is available at (www.fda.gov/cder/guidance/ 7086fnl.htm).
31. V. Ntziachristos, A. G. Yodh, M. Schnall, B. Chance, Proc. Natl. Acad. Sci. U.S.A. 97, 2767 (2000).
32. E. Nadler, B. Eckert, P. J. Neumann, Oncologist 11, 90 (2006).
33. S. Heinrich et al., Ann. Surg. 242, 235 (2005).
34. H. C. Kolb, K. B. Sharpless, Drug Discov. Today 8, 1128 (2003).
35. J. A. Joyce et al., Cancer Cell 4, 393 (2003).
36. D. G. Anderson, S. Levenberg, R. Langer, Nat. Biotechnol. 22, 863 (2004).
37. R. Weissleder, K. Kelly, E. Y. Sun, T. Shtatland, L. Josephson, Nat. Biotechnol. 23, 1418 (2005).
38. T. J. Meade, A. K. Taylor, S. R. Bull, Curr. Opin. Neurobiol. 13, 597 (2003).
39. M. Querol, J. W. Chen, R. Weissleder, A. J. Bogdanov, Org. Lett. 7, 1719 (2005).
40. R. Weissleder, C. H. Tung, U. Mahmood, A. Bogdanov Jr., Nat. Biotechnol. 17, 375 (1999).
41. V. Ntziachristos, J. Ripoll, L. V. Wang, R. Weissleder, Nat. Biotechnol. 23, 313 (2005).
42. M. Keller et al., Biol. Psychiatry 59, 216 (2006).
43. The author is a founder of and holds shares of stock in VisEn Medical, a company that is developing experimental imaging technologies. The author thanks U. Mahmood, M. Harisinghani, and R. Hargreaves for figures and all members of the Center for Molecular Imaging Research for many helpful discussions.